MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named ...
MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in ...
PacBio has announced a new study published in Nature Communications that presents an innovative method for analyzing complex regions of the human genome, particularly segmental duplications that have ...
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research ...
PacBio has announced plans to enhance its methylation detection capabilities in HiFi sequencing by licensing advanced methods from Professor Dennis Lo and his team at The Chinese University of Hong ...
PacBio (NASDAQ: PACB), announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic variation which characterizes simple and complex variation.
MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published ...
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide ALS is a progressive neurodegenerative ...
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.
PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results